IGF1R and neoplasm: Menu et al. [33, 34] demonstrated that picropodophyllin, a non-ATP-competitive IGF-1R tyrosine kinase inhibitor, inhibits tumor growth [33], MM-associated angiogenesis and bone disease [34] in 5T33MM-treated mice.